| Primary |
| Chronic Lymphocytic Leukaemia |
65.1% |
| Hypertension |
5.1% |
| Product Used For Unknown Indication |
5.1% |
| Prophylaxis |
3.7% |
| Urosepsis |
2.4% |
| B-cell Lymphoma |
2.1% |
| Drug Use For Unknown Indication |
2.1% |
| Diabetes Mellitus |
1.9% |
| Infection Prophylaxis |
1.9% |
| Osteoporosis Prophylaxis |
1.9% |
| Bacterial Infection |
1.6% |
| Hodgkin's Disease |
1.3% |
| Constipation |
1.1% |
| Toxoplasmosis |
1.0% |
| Pharyngitis Bacterial |
0.8% |
| Diabetes Prophylaxis |
0.6% |
| Supraventricular Tachycardia |
0.6% |
| Antifungal Prophylaxis |
0.5% |
| Asthma |
0.5% |
| Atrial Fibrillation |
0.5% |
|
| Pneumonia |
15.3% |
| Neutropenic Sepsis |
9.6% |
| Neutropenia |
7.2% |
| Vomiting |
7.2% |
| Febrile Neutropenia |
6.2% |
| Pyrexia |
5.7% |
| Sepsis |
4.8% |
| Thrombocytopenia |
4.8% |
| Gastroenteritis |
4.3% |
| Urinary Tract Infection |
4.3% |
| Haemolytic Anaemia |
3.8% |
| Renal Failure |
3.8% |
| Dyspnoea |
3.3% |
| Respiratory Failure |
3.3% |
| Respiratory Tract Infection |
3.3% |
| Pharyngitis Bacterial |
2.9% |
| Pleural Effusion |
2.9% |
| Empyema |
2.4% |
| Tremor |
2.4% |
| White Blood Cell Count Decreased |
2.4% |
|
| Secondary |
| Chronic Lymphocytic Leukaemia |
22.2% |
| Hodgkin's Disease |
20.4% |
| Drug Use For Unknown Indication |
11.9% |
| Product Used For Unknown Indication |
11.7% |
| Mantle Cell Lymphoma |
7.1% |
| B-cell Lymphoma |
6.2% |
| Non-hodgkin's Lymphoma |
4.5% |
| Waldenstrom's Macroglobulinaemia |
2.9% |
| Lymphoma |
2.7% |
| Rheumatoid Arthritis |
2.3% |
| Hodgkin's Disease Recurrent |
1.4% |
| Prophylaxis |
1.2% |
| Amyloidosis |
1.0% |
| Behcet's Syndrome |
0.8% |
| Thrombocytopenia |
0.8% |
| Plasma Cell Myeloma |
0.7% |
| Multiple Myeloma |
0.7% |
| Lymphocytic Leukaemia |
0.6% |
| Pulmonary Hypertension |
0.5% |
| Hypertension |
0.5% |
|
| Febrile Neutropenia |
12.9% |
| Cardiomyopathy |
7.6% |
| Myelodysplastic Syndrome |
6.2% |
| Pneumonia |
5.7% |
| Speech Disorder |
5.7% |
| Sepsis |
5.2% |
| Toxicity To Various Agents |
5.2% |
| Pyrexia |
4.8% |
| Acute Myeloid Leukaemia |
4.3% |
| Hyperglycaemia |
4.3% |
| Pleural Effusion |
4.3% |
| Thrombocytopenia |
4.3% |
| Vomiting |
4.3% |
| Colon Cancer |
3.8% |
| Diffuse Large B-cell Lymphoma |
3.8% |
| Leukoencephalopathy |
3.8% |
| Neutropenia |
3.8% |
| Acute Myelomonocytic Leukaemia |
3.3% |
| Progressive Multifocal Leukoencephalopathy |
3.3% |
| Respiratory Failure |
3.3% |
|
| Concomitant |
| Chronic Lymphocytic Leukaemia |
30.0% |
| Drug Use For Unknown Indication |
26.2% |
| Haemolysis |
5.2% |
| Non-hodgkin's Lymphoma |
4.3% |
| Chronic Lymphocytic Leukaemia Transformation |
4.2% |
| Mantle Cell Lymphoma |
3.1% |
| Product Used For Unknown Indication |
3.1% |
| Renal Disorder |
2.9% |
| B-cell Lymphoma |
2.8% |
| Prophylaxis |
2.4% |
| T-cell Lymphoma |
2.2% |
| Lymphoma |
2.0% |
| Waldenstrom's Macroglobulinaemia |
1.9% |
| Chronic Lymphocytic Leukaemia Refractory |
1.7% |
| Lymphocytic Lymphoma |
1.7% |
| B-cell Small Lymphocytic Lymphoma Refractory |
1.4% |
| Hodgkin's Disease |
1.4% |
| Hypertension |
1.4% |
| Antisynthetase Syndrome |
1.0% |
| Mycosis Fungoides |
1.0% |
|
| Progressive Multifocal Leukoencephalopathy |
24.1% |
| Acute Myeloid Leukaemia |
9.3% |
| Viral Infection |
8.3% |
| Paraesthesia |
6.5% |
| Septic Shock |
5.6% |
| Thrombocytopenia |
5.6% |
| Neutropenia |
4.6% |
| Respiratory Tract Infection Viral |
4.6% |
| Neuroendocrine Carcinoma |
3.7% |
| Pancytopenia |
3.7% |
| Death |
2.8% |
| Renal Failure |
2.8% |
| Staphylococcal Infection |
2.8% |
| Status Epilepticus |
2.8% |
| Vascular Calcification |
2.8% |
| Vision Blurred |
2.8% |
| Acute Myelomonocytic Leukaemia |
1.9% |
| Asthenia |
1.9% |
| Dermatitis Allergic |
1.9% |
| Dysarthria |
1.9% |
|
